🧬 Interested in pharma, biotech and medical device news? Visit PharmaDeviceNews.com →
Browsing Tag

Amsterdam

39 posts
Read More

Adyen (AMS: ADYEN) processes €451bn, drops 13%. Why abandon its margin goal?

Adyen delivered 23% net revenue growth and processed €451.1 billion in payments, yet its shares plunged after management reduced profitability guidance and abandoned its medium-term EBITDA margin target. The decision raises a critical question about whether expanding into billing, loyalty and AI-enabled commerce will justify sacrificing near-term margins.
Read More

Nebius (NASDAQ: NBIS) has $40bn in AI contracts. Why borrow $3.5bn for one year?

Nebius Group has secured a US$3.5 billion financing facility to accelerate its artificial intelligence infrastructure expansion, despite having more than US$40 billion in long-term customer commitments. The one-year maturity, floating interest rate and secured borrowing structure raise an important question about how the company plans to finance its next phase of growth.